Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will participate in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2, 2021. The management team will hold investor meetings on December 1, 2021, and a pre-recorded fireside chat will be available on the company’s website starting November 22, 2021. Pulmonx is recognized for its minimally invasive treatments for severe lung disease, including the Zephyr® Endobronchial Valve, which has been used in over 100,000 procedures worldwide. For more information, visit Pulmonx Investors.

REDWOOD CITY, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) --  Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will participate in the 33^rd Annual Piper Sandler Healthcare Conference being held from November 29 to December 2, 2021. Members of the management team will be participating in investor meetings on Wednesday, December 1, 2021.

Pulmonx management will also participate in a pre-recorded fireside chat, which will be available beginning Monday, November 22^nd at 7:00AM PT / 10:00AM ET on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When will Pulmonx participate in the Piper Sandler Healthcare Conference?

Pulmonx will participate in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2, 2021.

What is the date for Pulmonx's investor meetings?

Pulmonx's investor meetings are scheduled for December 1, 2021.

When will the fireside chat be available on Pulmonx's website?

The pre-recorded fireside chat will be available starting November 22, 2021, at 7:00 AM PT.

What is the stock symbol for Pulmonx Corporation?

The stock symbol for Pulmonx Corporation is LUNG.

What treatments does Pulmonx offer for lung disease?

Pulmonx offers treatments like the Zephyr® Endobronchial Valve, designed for patients with severe emphysema/COPD.

How many Zephyr Valves have been used in treatments?

Over 100,000 Zephyr Valves have been used to treat more than 25,000 patients.